Prospective Multicenter Randomized Intermediate Biomarker Study of Oral Contraceptive versus Depo-Provera for Prevention of Endometrial Cancer in Women with Lynch Syndrome
Authors:
- Karen H. LuKLKaren H. Lu
- David S. LooseDLDavid S. Loose
- Melinda S. YatesMYMelinda S. Yates
- Graciela M. Nogueras-GonzalezGNGraciela M. Nogueras-Gonzalez
- Mark F. MunsellMMMark F. Munsell
- Lee-May ChenLCLee-May Chen
- Henry LynchHLHenry Lynch
- Terri CornelisonTCTerri Cornelison
- Stephanie Boyd-RogersSBStephanie Boyd-Rogers
- Mary RubinMRMary Rubin
- Molly S. DanielsMDMolly S. Daniels
- Peggy ConradPCPeggy Conrad
- 1 August 2013
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 6 (8) , 774-781
Abstract
Women with Lynch syndrome have a 40% to 60% lifetime risk for developing endometrial cancer, a cancer associated with estrogen imbalance. The molecular basis for endometrial-specific tumorigenesis is unclear. Progestins inhibit estrogen-driven proliferation, and epidemiologic studies have shown that progestin-containing oral contraceptives (OCP) reduce the risk of endometrial cancer by 50% in women at general population risk. It is unknown whether they are effective in women with Lynch syndrome. Asymptomatic women ages 25 to 50 with Lynch syndrome were randomized to receive the progestin compounds Depo-Provera (depo-MPA) or OCP for three months. An endometrial biopsy and transvaginal ultrasound were conducted before and after treatment. Endometrial proliferation was evaluated as the primary endpoint. Histology and a panel of surrogate endpoint biomarkers were evaluated for each endometrial biopsy as secondary endpoints. A total of 51 women were enrolled, and 46 completed treatment. Two of the 51 women had complex hyperplasia with atypia at the baseline endometrial biopsy and were excluded from the study. Overall, both depo-MPA and OCP induced a dramatic decrease in endometrial epithelial proliferation and microscopic changes in the endometrium characteristic of progestin action. Transvaginal ultrasound measurement of endometrial stripe was not a useful measure of endometrial response or baseline hyperplasia. These results show that women with Lynch syndrome do show an endometrial response to short-term exogenous progestins, suggesting that OCP and depo-MPA may be reasonable chemopreventive agents in this high-risk patient population. Cancer Prev Res; 6(8); 774–81. ©2013 AACR.Keywords
All Related Versions
This publication has 27 references indexed in Scilit:
- Sex hormone regulation of survivin gene expressionJournal of Endocrinology, 2010
- Risk of unanticipated abnormal gynecologic pathology at the time of hysterectomy for uterovaginal prolapseAmerican Journal of Obstetrics and Gynecology, 2010
- Molecular clustering of endometrial carcinoma based on estrogen-induced gene expressionCancer Biology & Therapy, 2009
- DNA methylation inhibits p53-mediated survivin repressionOncogene, 2009
- Secreted Frizzled-Related Protein 4 Regulates Two Wnt7a Signaling Pathways and Inhibits Proliferation in Endometrial Cancer CellsMolecular Cancer Research, 2008
- Developmental reprogramming of IGF signaling and susceptibility to endometrial hyperplasia in the ratLaboratory Investigation, 2008
- Wnt7a interaction with Fzd5 and detection of signaling activation using a split eGFPBiochemical and Biophysical Research Communications, 2008
- Overexpression of the Insulin-Like Growth Factor I Receptor and Activation of the AKT Pathway in Hyperplastic EndometriumClinical Cancer Research, 2006
- Prophylactic Surgery to Reduce the Risk of Gynecologic Cancers in the Lynch SyndromeNew England Journal of Medicine, 2006
- Identification of a Novel Estrogen-Regulated Gene, EIG121, Induced by Hormone Replacement Therapy and Differentially Expressed in Type I and Type II Endometrial CancerClinical Cancer Research, 2005